Cargando…

Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation

The SH2 domain of cytoplasmic tyrosine kinases can enhance catalytic activity and substrate recognition, but the molecular mechanisms by which this is achieved are poorly understood. We have solved the structure of the prototypic SH2-kinase unit of the human Fes tyrosine kinase, which appears specia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippakopoulos, Panagis, Kofler, Michael, Hantschel, Oliver, Gish, Gerald D., Grebien, Florian, Salah, Eidarus, Neudecker, Philipp, Kay, Lewis E., Turk, Benjamin E., Superti-Furga, Giulio, Pawson, Tony, Knapp, Stefan
Formato:	Texto
Lenguaje:	English
Publicado:	Cell Press 2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572732/ https://www.ncbi.nlm.nih.gov/pubmed/18775312 http://dx.doi.org/10.1016/j.cell.2008.07.047

Ejemplares similares

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
por: Grebien, Florian, et al.
Publicado: (2011)

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
por: Mian, Afsar A., et al.
Publicado: (2019)

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
por: Wojcik, John, et al.
Publicado: (2010)

SH2 domains: modulators of nonreceptor tyrosine kinase activity
por: Filippakopoulos, Panagis, et al.
Publicado: (2009)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Structural and Functional Characterization of the Human Protein Kinase ASK1
por: Bunkoczi, Gabor, et al.
Publicado: (2007)

The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion
por: Dölker, Nicole, et al.
Publicado: (2014)

Cell biology: A key driver of therapeutic innovation
por: Hantschel, Oliver, et al.
Publicado: (2012)

Bcr-Abl: one kinase, two isoforms, two diseases
por: Reckel, Sina, et al.
Publicado: (2017)

Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial Homeostasis
por: Hopkins, Sarah, et al.
Publicado: (2012)

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
por: Schmidt, Nina, et al.
Publicado: (2022)

SH2 and SH3 domains
por: Pawson, Tony
Publicado: (1992)

The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response
por: Soulat, Didier, et al.
Publicado: (2008)

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
por: Winger, Jonathan A, et al.
Publicado: (2009)

Conformational Determinants of Phosphotyrosine Peptides Complexed with the Src SH2 Domain
por: Nachman, Joseph, et al.
Publicado: (2010)

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition
por: Soundararajan, Meera, et al.
Publicado: (2013)

Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class
por: Salah, Eidarus, et al.
Publicado: (2011)

Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3
por: Schröder, Martin, et al.
Publicado: (2020)

A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
por: Burkard, Thomas R., et al.
Publicado: (2010)

Identification of a Major Determinant for Serine-Threonine Kinase Phosphoacceptor Specificity
por: Chen, Catherine, et al.
Publicado: (2014)

Identifying Kinase Substrates via a Heavy ATP Kinase Assay and Quantitative Mass Spectrometry
por: Müller, André C., et al.
Publicado: (2016)

Building and exploring an integrated human kinase network: Global organization and medical entry points()
por: Colinge, Jacques, et al.
Publicado: (2014)

Selective Targeting of SH2 Domain–Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies
por: Kükenshöner, Tim, et al.
Publicado: (2017)

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
por: Reckel, S, et al.
Publicado: (2017)

Bromodomains as therapeutic targets
por: Muller, Susanne, et al.
Publicado: (2011)

Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms
por: Duarte, Daniel P., et al.
Publicado: (2020)

Intramolecular Dynamics within the N-Cap-SH3-SH2 Regulatory Unit of the c-Abl Tyrosine Kinase Reveal Targeting to the Cellular Membrane
por: de Oliveira, Guilherme A. P., et al.
Publicado: (2013)

Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs
por: Eswaran, Jeyanthy, et al.
Publicado: (2007)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

Structure of the CaMKIIδ/Calmodulin Complex Reveals the Molecular Mechanism of CaMKII Kinase Activation
por: Rellos, Peter, et al.
Publicado: (2010)

Kinase-templated abiotic reaction
por: Saarbach, J., et al.
Publicado: (2017)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Establishing the role of the FES tyrosine kinase in the pathogenesis, pathophysiology, and severity of sepsis and its outcomes
por: Laight, Brian J., et al.
Publicado: (2023)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
por: Ciceri, Pietro, et al.
Publicado: (2014)

7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes†
por: Huber, Kilian, et al.
Publicado: (2011)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases
por: Myrianthopoulos, Vassilios, et al.
Publicado: (2012)

Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis
por: van der Wel, Tom, et al.
Publicado: (2020)

Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase
por: Iacob, Roxana E., et al.
Publicado: (2011)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_17n0ia8has5drrlic63lck1ic7